drugset

drugset / Trial / NCT00130312

Effect of Sulodexide in Overt Diabetic Nephropathy

NCT00130312 ↗

Phase 4 Terminated 968 enrolled Keryx Biopharmaceuticals Collaborative Study Group (CSG) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether sulodexide is effective in slowing or preventing the progression of diabetic kidney disease.

Timeline

Start: 2005-08
Primary completion: 2008-03
Completion: 2008-03

Outcome

Outcome not reported

Stopped: “No difference in protein excretion at 6\&12 months. No safety issues.”

Publications

Bidadkosh A, Lambooy SPH, Heerspink HJ, Pena MJ, Henning RH, Buikema H, Deelman LE. Predictive Properties of Biomarkers GDF-15, NTproBNP, and hs-TnT for Morbidity and Mortality in Patients With Type 2 Diabetes With Nephropathy. Diabetes Care. 2017 Jun;40(6):784-792. doi: 10.2337/dc16-2175. Epub 2017 Mar 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sulodexide	Other / unclassified	100 mg	—

Indications